Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-04-11 Sale | 2024-04-15 7:04 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $24.72 | $346,149 | 225,370 (Direct) | View |
| 2024-03-27 Sale | 2024-03-29 5:59 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $18.25 | $59,302 | 239,370 (Direct) | View |
| 2024-02-27 Sale | 2024-02-29 5:27 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $16.97 | $55,163 | 242,620 (Direct) | View |
| 2024-01-29 Sale | 2024-01-31 9:20 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $15.81 | $51,388 | 245,870 (Direct) | View |
| 2023-12-28 Sale | 2024-01-02 7:59 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 11,870 | $15.02 | $178,327 | 766,146 (Direct) | View |
| 2023-12-22 Sale | 2023-12-27 5:26 pm | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 1,130 | $15.07 | $17,025 | 522,080 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-04-11 Exercise | 2024-04-15 7:04 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $0 | 225,370 (Direct) | View |
| 2024-04-11 Exercise | 2024-04-15 7:04 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 14,000 | $2.48 | 225,370 (Direct) | View |
| 2024-03-27 Exercise | 2024-03-29 5:59 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 239,370 (Direct) | View |
| 2024-03-27 Exercise | 2024-03-29 5:59 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 239,370 (Direct) | View |
| 2024-02-27 Exercise | 2024-02-29 5:27 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 242,620 (Direct) | View |
| 2024-02-27 Exercise | 2024-02-29 5:27 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 242,620 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:54 pm | N/A 2034-02-12 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 185,000 | $0 | 185,000 (Direct) | View |
| 2024-01-29 Exercise | 2024-01-31 9:20 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $0 | 245,870 (Direct) | View |
| 2024-01-29 Exercise | 2024-01-31 9:20 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER | 3,250 | $2.48 | 245,870 (Direct) | View |
| 2023-12-28 Exercise | 2024-01-02 7:59 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 11,870 | $0 | 766,146 (Direct) | View |
| 2023-12-28 Exercise | 2024-01-02 7:59 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 11,870 | $2.48 | 766,146 (Direct) | View |
| 2023-12-22 Exercise | 2023-12-27 5:26 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 1,130 | $0 | 522,080 (Direct) | View |
| 2023-12-22 Exercise | 2023-12-27 5:26 pm | N/A N/A | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 1,130 | $2.48 | 522,080 (Direct) | View |
| 2023-04-04 Option Award | 2023-04-06 8:32 pm | N/A 2033-04-04 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 206,000 | $0 | 206,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-27 9:33 pm | N/A 2031-08-02 | Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer | 262,120 | $0 | 262,120 (Direct) | View |